by Truveta staff | Oct 9, 2025 | Data
Major depressive disorder (MDD) is one of the most urgent and costly public health challenges today. More than 18% of US adults live with depression, and rates are even higher among younger adults. Despite advances in pharmacology, psychotherapy, and neuromodulation,...
by Truveta staff | Oct 3, 2025 | Data
The US Food and Drug Administration (FDA) recently published a comprehensive overview of how real-world evidence (RWE) has contributed to regulatory decision-making since 2011. The new webpage, built by the Center for Drug Evaluation and Research (CDER) and the Center...
by Truveta staff | Sep 12, 2025 | Data
Non–small cell lung cancer (NSCLC) accounts for about 85% of lung cancer cases and remains the leading cause of cancer death worldwide. While major advances in targeted therapies and immunotherapies have transformed care, gaps persist in biomarker testing, treatment...
by Truveta staff | Aug 25, 2025 | Data
Multiple sclerosis (MS) affects approximately 1 million people in the United States, with women representing nearly 75% of patients. Over the past decade, consensus guidelines from leading MS experts have increasingly emphasized the importance of early intervention...
by Truveta staff | Aug 18, 2025 | Data
After years of uncertainty, a recent policy change is sparking new optimism in rare disease drug development. A change in federal policy now keeps certain multi-indication rare therapies exempt from Medicare price negotiations—a rule that had discouraged some...
by Truveta staff | Aug 4, 2025 | Data
Why do patients stop taking a medication? Was it due to side effects, access barriers, or lack of efficacy? These are not just clinical questions; they’re strategic ones. Understanding treatment discontinuation is essential for improving therapy design, informing...
